TokenPost·
AbbVie Seeks FDA Review of Etentamig for Relapsed or Refractory Myeloma
In Phase 3 CERVINO, the response rate was 74.0% with etentamig and 45.7% with standard therapy after a median 11.4 months of follow-up.
More news
- TokenPostCFTC Probes Whether Polymarket Breached 2022 U.S. User Ban
- TokenPostECB Warns of Fraudulent Letters Tied to Digital Euro Pilot
- TokenPostMizuho Calls Life Time Group Holdings, Inc. a Top Pick Before Q3 Results
- TokenPostXylem Cuts 2026 Revenue Outlook to $8.95 Billion, Adjusted EPS to $5.40-$5.45
- TokenPostU.S. Refinery Use Hits May-to-September High Since 1998 Before Phillips 66 Q3 Report
- TokenPostAvidbank Expects $270 Million Deposit Outflow in Q4, Beta Below 50%